IONS IONIS PHARMACEUTICALS INC
Price Chart
Executive Summary
Ionis partner GSK reported positive Phase 3 data for bepirovirsen in chronic hepatitis B, showing a 19% functional cure rate vs 0% for standard of care. The drug is under priority FDA review with decisions expected in Q3 2026, and Ionis is eligible for tiered royalties of 10-12% on net sales plus milestones.
Actionable Insight
This is a transformative pipeline catalyst for Ionis. The 19% functional cure rate vs <1% standard of care positions bepirovirsen as a potential blockbuster in a 240M+ patient market. Monitor FDA decision in Q3 2026 and GSK's launch preparations. The royalty stream could meaningfully impact Ionis revenue starting 2027.
Key Facts
- Bepirovirsen achieved 19% functional cure rate (233/1,220) vs 0% placebo in pooled Phase 3 B-Well 1 & 2 trials (p<0.001)
- In patients with baseline HBsAg ≤1000 IU/mL, functional cure rate was 26% (200/768) vs 0% placebo
- Current standard of care achieves functional cure in <1% of patients
- FDA priority review with Breakthrough and Fast Track Designation; first regulatory decisions expected Q3 2026
- Ionis receives tiered royalties of 10-12% on net sales of bepirovirsen plus milestone payments
- Results published in NEJM and presented at EASL congress
Financial Impact
Ionis eligible for tiered royalties of 10-12% on net sales plus additional regulatory and sales milestone payments; no specific dollar amounts disclosed
Risk Factors
- FDA or other regulatory agencies could reject or delay approval
- Commercial adoption may be slower than expected despite strong efficacy data
- Competing hepatitis B therapies in development could limit market share
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-023093 |
| Document: ef20075060_ex99-1.htm | 0001140361-26-023093 |
| Document: 0001140361-26-023093-index-headers.html | 0001140361-26-023093 |
| Document: 0001140361-26-023093-index.html | 0001140361-26-023093 |
| Document: 0001140361-26-023093.txt | 0001140361-26-023093 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 16, 2026
4d ago
|
Insider Cluster
| $74.31 $74.12 | ▼ −0.26% | ▼ −1.04% | $74.31 (−0.00%) |
|
Jun 12, 2026
8d ago
|
8-K
| $73.28 $73.96 | ▲ +0.93% | ▼ −0.83% | $74.31 (+1.41%) |
|
Jun 8, 2026
12d ago
|
8-K
| $73.54 $74.58 | ▲ +1.41% | ▲ +1.71% | $74.31 (+1.05%) |
|
May 28, 2026
23d ago
|
8-K
| $77.27 $76.29 | ▼ −1.27% | ▼ −1.51% | $74.31 (−3.83%) |
|
Apr 28, 2026
7w ago
|
Insider Cluster
| $71.50 $74.37 | ▲ +4.01% | ▲ +4.02% | $74.31 (+3.93%) |
|
Apr 21, 2026
8w ago
|
8-K
| $74.71 $74.84 | ▲ +0.17% | ▼ −0.84% | $74.31 (−0.54%) |
|
Apr 16, 2026
9w ago
|
Insider Cluster
| $75.25 $75.71 | ▲ +0.61% | ▼ −0.61% | $74.31 (−1.25%) |
|
Feb 25, 2026
16w ago
|
8-K
| $80.87 $80.34 | ▼ −0.66% | ▼ −0.11% | $74.31 (−8.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access